Skip to Content

Idhifa Side Effects

Generic Name: enasidenib

Note: This document contains side effect information about enasidenib. Some of the dosage forms listed on this page may not apply to the brand name Idhifa.

For the Consumer

Applies to enasidenib: oral tablet

Along with its needed effects, enasidenib (the active ingredient contained in Idhifa) may cause some unwanted effects. Although not all of these side effects may occur, if they do occur they may need medical attention.

Check with your doctor immediately if any of the following side effects occur while taking enasidenib:

More Common

  • Agitation
  • blue lips, fingernails, or skin
  • bone pain
  • chest pain
  • chills
  • confusion
  • cough
  • coughing that sometimes produces a pink frothy sputum
  • decreased awareness or responsiveness
  • decreased urine output
  • depression
  • difficult or troubled breathing
  • difficult, fast, noisy breathing
  • dizziness
  • eye pain
  • fainting
  • fast heartbeat
  • fever
  • general feeling of illness
  • headache
  • hostility
  • increased sweating
  • irregular, fast or slow, or shallow breathing
  • irritability
  • lightheadedness
  • loss of consciousness
  • muscle or joint pain
  • muscle twitching
  • nausea
  • pale skin
  • rapid weight gain
  • rapid, shallow breathing
  • seizures
  • severe sleepiness
  • sore throat
  • swelling around the neck, groin, or underarm area
  • swelling of the arms, feet, or lower legs
  • swelling of the face, ankles, or hands
  • unusual drowsiness, dullness, tiredness, weakness or feeling of sluggishness
  • yellow skin or eyes

Some side effects of enasidenib may occur that usually do not need medical attention. These side effects may go away during treatment as your body adjusts to the medicine. Also, your health care professional may be able to tell you about ways to prevent or reduce some of these side effects. Check with your health care professional if any of the following side effects continue or are bothersome or if you have any questions about them:

More Common

For Healthcare Professionals

Applies to enasidenib: oral tablet


The most common (30% or more) adverse reactions of any grade were elevated bilirubin, decreased calcium and potassium levels, nausea, diarrhea, vomiting, and decreased appetite.[Ref]


Very common (10% or more): Increased total bilirubin (81%)[Ref]


Very common (10% or more): Decreased calcium (74%), decreased potassium (41%), decreased appetite (34%), decreased phosphorus (27%)

Common (1% to 10%): Tumor lysis syndrome, decreased weight[Ref]


Very common (10% or more): Nausea (50%), diarrhea (43%), vomiting (34%)

Common (1% to 10%): Abdominal pain[Ref]


Very common (10% or more): Differentiation syndrome (14%), noninfectious leukocytosis (12%)[Ref]

Nervous system

Very common (10% or more): Dysgeusia (12%)[Ref]


Common (1% to 10%): Rash[Ref]


Common (1% to 10%): Increased uric acid[Ref]


Common (1% to 10%): Pyrexia, peripheral edema[Ref]


Common (1% to 10%): Renal insufficiency[Ref]


Common (1% to 10%): Respiratory failure, dyspnea, hypoxia, pulmonary edema, acute respiratory distress syndrome[Ref]


1. "Product Information. Idhifa (enasidenib)." Celgene Corporation, Summit, NJ.

Further information

Always consult your healthcare provider to ensure the information displayed on this page applies to your personal circumstances.

Some side effects may not be reported. You may report them to the FDA.